Navbar

Guidelines
Compendia & Templates
Education & Research
Patient Resources
Business & Policy
Global

Guidelines Treatment by Cancer Type Detection, Prevention, and Risk Reduction Supportive Care Specific Populations Guidelines for Patients Guidelines With Evidence Blocks NCCN Framework For Resource Stratification Harmonized Guidelines International Adaptations and Translations NCCN Mobile Apps Guidelines Process Guidelines Panels and Disclosure Permission to Cite or Use NCCN Content Recently Updated Guidelines Submission Request to the Guidelines Panels Order Free Print Copies

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Melanoma: Cutaneous Melanoma: Uveal Merkel Cell Carcinoma Mesothelioma: Peritoneal Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas

Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)

Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening

Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Lung Cancer Screening

Prostate Cancer Early Detection

Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue

Distress Management Hematopoietic Cell Transplantation Hematopoietic Growth Factors Management of Immunotherapy-Related Toxicities

Palliative Care Prevention and Treatment of Cancer-Related Infections Smoking Cessation Survivorship

Adolescent and Young Adult (AYA) Oncology

Cancer in People with HIV

Older Adult Oncology

Acute Lymphoblastic Leukemia (adult) Acute Lymphoblastic Leukemia (pediatric) Acute Myeloid Leukemia Adolescent and Young Adult Cancer Adrenal Tumors Anal Cancer Anemia and Neutropenia - Low Red and White Blood Cell Counts Basal Cell Skin Cancer Bladder Cancer Blood Clots and Cancer Bone Cancer Brain Cancer - Glioma Breast Cancer - Ductal Carcinoma In Situ Breast Cancer - Inflammatory Breast Cancer Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Breast Cancer Screening and Diagnosis Cervical Cancer Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Colon Cancer Colorectal Cancer Screening Cutaneous B-Cell Lymphomas Cutaneous T-Cell Lymphomas Diffuse Large B-Cell Lymphomas

Distress During Cancer Care Esophageal Cancer Fatigue and Cancer Follicular Lymphoma Gallbladder and Bile Duct Cancers Gastrointestinal Stromal Tumors (GIST) Graft-Versus-Host Disease Hodgkin Lymphoma Hodgkin Lymphoma in Children Immunotherapy Side Effects: CAR T-Cell Therapy Immunotherapy Side Effects: Immune Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Mantle Cell Lymphoma Marginal Zone Lymphomas Melanoma: Cutaneous - Melanoma Mesothelioma: Pleural - Malignant Pleural Mesothelioma Mouth Cancer Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal Cancer Nausea and Vomiting Neuroendocrine Tumors

Non-Small Cell Lung Cancer - Early and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Palliative Care Pancreatic Cancer Peripheral T-Cell Lymphoma Primary Central Nervous System Lymphoma Prostate Cancer: Advanced Stage Prostate Cancer: Early Stage Quitting Smoking Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Stomach Cancer Survivorship Care for Cancer-Related Late and Long-Term Effects Survivorship Care for Healthy Living Systemic Mastocytosis Throat Cancer Thyroid Cancer Uterine Cancer Waldenström Macroglobulinemia

About Clinical Practice Guidelines Development and Update of Guidelines

Transparency Process Guidelines Panels Meeting Schedule

Disclosure Policies and Potential Conflicts of Interest

Guidelines Panels

Guideline Steering Committee

Submission Request History

My Submission Request

Submission Request Form

Compendia & Templates Compendia Chemotherapy Order Templates

NCCN Compendia Drugs and Biologics Compendium

Biomarkers Compendium Imaging AUC Compendium

Radiation Therapy Compendium Subscribe to NCCN Compendium

Browse by Cancer Type View Chemotherapy Order Templates User Guide

EHR Integration Chemotherapy Order Templates Committee

Subscribe to NCCN Templates Chemotherapy Order Templates Reviewer Acknowledgement

Education & Research Events and Programs Oncology Research Program JNCCN Publications

Continuing Education Calendar of Events Annual Conference

2025 Annual Conference Exhibitor Prospectus Annual Congress: Hematologic Malignancies Nursing Events

Share that You are Attending an NCCN Event 2025 Breast Cancer Congress

Oncology Research Program (ORP) Current Opportunities ORP Recent News ORP Grant History

Scientific Publications Clinical Trials Young Investigator Awards Informed Consent Language Database

Best Practices for Biorepositories Shared Resources Disclosure Policy

About JNCCN

Subscribe to JNCCN

JNCCN Email Updates

Business & Policy Business Policy and Advocacy Program

Corporate Council Academy Trends U.S. Surveys Trends Global Surveys Flash Updates

Order Free Pocket Guidelines and Patient Guidelines Support Opportunities Advertising Opportunities Research Tools: REMS Employer Resources

Virtual Reimbursement Resource Room and App Health Information Technology Licenses Embargo Policy Firewall Policy

Policy and Advocacy Program Policy Priorities NCCN Findings on Cancer Drug Shortages

Advancing Cancer Equity NCCN Diversity, Equity, and Inclusion (DEI) Directors Forum Oncology Policy Summits

State Oncology Society Forum

Global Global Program Global Clinical Resources Global Support Opportunities Global Policy Contact NCCN Global

Africa Asia

Europe Latin America

Middle East & North Africa Worldwide

Clinical Guidelines Translations Guidelines for Patients Translations Distress Thermometer Tool Translations

International Adaptations Framework for Resource Stratification Harmonized Guidelines

Cancer Care and Humanitarian Crises

Global Corporate Council Global Academy

Trends Global Surveys eBulletin Global Edition

Home
Guidelines
Guidelines Process
Transparency Document

Transparency Document

NCCN Guidelines for Anal Carcinoma V.1.2025

Request Number	Guideline Page	Specific change request	Panel Decision	Comment	Institution Vote
4540	ANAL-B (page 2 of 3) Retifanlimab-dlwr Submission from Incyte Corporation on 09-16-2024	We request the NCCN Panel to please consider adding retifanlimab-dlwr in combination with carboplatin and paclitaxel as the Category 2A, preferred first-line treatment option for metastatic disease. All supporting references have been attached for your review and inclusion.	Change made	This is a category 2B, other recommended regimen	Yes: 11 No: 5 Abstain:8 Absent:10

Request Number

Guideline Page

Specific change request

Panel Decision

Comment

Institution Vote

4540

ANAL-B (page 2 of 3)
Retifanlimab-dlwr Submission from Incyte Corporation on 09-16-2024

We request the NCCN Panel to please consider adding retifanlimab-dlwr in combination with carboplatin and paclitaxel as the Category 2A, preferred first-line treatment option for metastatic disease.

All supporting references have been attached for your review and inclusion.

Change made

This is a category 2B, other recommended regimen

Yes: 11
No: 5
Abstain:8
Absent:10